<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Stellar Biotechnologies, Inc.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:e8cc4acd-9732-4ce4-b3ae-66f0ea2be822;id=1721</id> <rights type="text">Copyright 2017, Stellar Biotechnologies, Inc.</rights> <updated>2017-01-11T12:30:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/SVSJNYX4iIEgtX06nbOd3Q==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/SVSJNYX4iIEgtX06nbOd3Q==" /> <entry> <id>https://www.globenewswire.com/news-release/2017/01/11/1051576/0/en/Stellar-Biotechnologies-Advances-Strategic-Plan-to-Secure-Key-Production-Region.html</id> <title type="text">Stellar Biotechnologies Advances Strategic Plan to Secure Key Production Region </title> <published>2017-01-11T12:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/11/1051576/0/en/Stellar-Biotechnologies-Advances-Strategic-Plan-to-Secure-Key-Production-Region.html" /> <content type="html"><![CDATA[<p>LOS ANGELES, CA--(Marketwired - Jan 11, 2017) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that the company has completed key steps under its strategic initiative to expand production of its Stellar KLH products.</p>]]></content> <dc:identifier>1051576</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/04/1051574/0/en/Stellar-Biotechnologies-to-Present-at-Biotech-Showcase-Conference.html</id> <title type="text">Stellar Biotechnologies to Present at Biotech Showcase Conference </title> <published>2017-01-04T12:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/04/1051574/0/en/Stellar-Biotechnologies-to-Present-at-Biotech-Showcase-Conference.html" /> <content type="html"><![CDATA[<p>LOS ANGELES, CA--(Marketwired - Jan 4, 2017) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual Biotech Showcase conference to be held January 9 - 11, 2017 in San Francisco, California.</p>]]></content> <dc:identifier>1051574</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/14/1051572/0/en/Stellar-Biotechnologies-Reports-Fiscal-Year-2016-Financial-Results.html</id> <title type="text">Stellar Biotechnologies Reports Fiscal Year 2016 Financial Results </title> <published>2016-12-14T21:05:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/14/1051572/0/en/Stellar-Biotechnologies-Reports-Fiscal-Year-2016-Financial-Results.html" /> <content type="html"><![CDATA[<p><em><p>Broader customer base drives higher product sales volumes and revenue</p></em></p><p>LOS ANGELES, CA--(Marketwired - Dec 14, 2016) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today reported financial results for the fiscal year ended September 30, 2016 and provided an update on its business.</p>]]></content> <dc:identifier>1051572</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/12/1051568/0/en/Stellar-Biotechnologies-Announces-Fiscal-Year-2016-Corporate-Update-Conference-Call.html</id> <title type="text">Stellar Biotechnologies Announces Fiscal Year 2016 Corporate Update Conference Call </title> <published>2016-12-12T12:45:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/12/1051568/0/en/Stellar-Biotechnologies-Announces-Fiscal-Year-2016-Corporate-Update-Conference-Call.html" /> <content type="html"><![CDATA[<p>LOS ANGELES, CA--(Marketwired - Dec 12, 2016) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, will host a conference call and live webcast on Thursday, December 15, 2016 at 1:30 p.m. ET (10:30 a.m. PT) to discuss its fiscal year 2016 results and to provide an update on its business.</p>]]></content> <dc:identifier>1051568</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/09/1051566/0/en/Stellar-Biotechnologies-Appoints-Pharma-and-Capital-Markets-Experts-to-Board-of-Directors.html</id> <title type="text">Stellar Biotechnologies Appoints Pharma and Capital Markets Experts to Board of Directors </title> <published>2016-12-09T12:45:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/09/1051566/0/en/Stellar-Biotechnologies-Appoints-Pharma-and-Capital-Markets-Experts-to-Board-of-Directors.html" /> <content type="html"><![CDATA[<p>LOS ANGELES, CA--(Marketwired - Dec 9, 2016) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced the appointment of Charles V. Olson, D.Sc. and Paul Chun to the company's Board of Directors.</p>]]></content> <dc:identifier>1051566</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/01/1051565/0/en/Stellar-Biotechnologies-to-Present-at-the-LD-Micro-Main-Event-Investor-Conference.html</id> <title type="text">Stellar Biotechnologies to Present at the LD Micro Main Event Investor Conference </title> <published>2016-12-01T12:45:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/01/1051565/0/en/Stellar-Biotechnologies-to-Present-at-the-LD-Micro-Main-Event-Investor-Conference.html" /> <content type="html"><![CDATA[<p>LOS ANGELES, CA--(Marketwired - Dec 1, 2016) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual LD Micro Main Event investor conference to be held December 6-8, 2016 in Los Angeles, California.</p>]]></content> <dc:identifier>1051565</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/24/1051562/0/en/Stellar-Board-Member-and-Pharma-Expert-to-Join-Executive-Team.html</id> <title type="text">Stellar Board Member and Pharma Expert to Join Executive Team </title> <published>2016-10-24T11:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/24/1051562/0/en/Stellar-Board-Member-and-Pharma-Expert-to-Join-Executive-Team.html" /> <content type="html"><![CDATA[<p><em><p>Appointment to lead company's expansion plans for supporting clinical drug development</p></em></p><p>LOS ANGELES, CA--(Marketwired - Oct 24, 2016) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, announced today that Gregory T. Baxter, PhD, will join the company's management team in the new role of Executive Vice President of Corporate Development, effective December 1, 2016. </p>]]></content> <dc:identifier>1051562</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/10/05/1051560/0/en/Stellar-Appoints-Investor-Relations-Executive-to-Management-Team-to-Support-Its-Continuing-Scale-Up.html</id> <title type="text">Stellar Appoints Investor Relations Executive to Management Team to Support Its Continuing Scale-Up </title> <published>2016-10-05T12:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/10/05/1051560/0/en/Stellar-Appoints-Investor-Relations-Executive-to-Management-Team-to-Support-Its-Continuing-Scale-Up.html" /> <content type="html"><![CDATA[<p>LOS ANGELES, CA--(Marketwired - Oct 5, 2016) - Stellar Biotechnologies, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, announced today that Gary Koppenjan has joined the company as Senior Director of Investor Relations and Communications. </p>]]></content> <dc:identifier>1051560</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/09/21/1051558/0/en/Stellar-Biotechnologies-to-Present-at-International-Aquaculture-Symposium.html</id> <title type="text">Stellar Biotechnologies to Present at International Aquaculture Symposium </title> <published>2016-09-21T12:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/09/21/1051558/0/en/Stellar-Biotechnologies-to-Present-at-International-Aquaculture-Symposium.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - Sep 21, 2016) - <strong> Stellar Biotechnologies, Inc. ("Stellar" or "the Company") </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), will present at the VIII Simposio Internacional de Sanidad e Inocuidad Acuícola (VIII International Symposium on Aquaculture Health and Safety) in Ensenada, Baja California, Mexico, September 22-23, 2016.</p>]]></content> <dc:identifier>1051558</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/09/06/1051557/0/en/Stellar-Biotechnologies-to-Present-at-the-18th-Rodman-Renshaw-2016-Annual-Global-Investment-Conference.html</id> <title type="text">Stellar Biotechnologies to Present at the 18th Rodman & Renshaw 2016 Annual Global Investment Conference </title> <published>2016-09-06T12:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/09/06/1051557/0/en/Stellar-Biotechnologies-to-Present-at-the-18th-Rodman-Renshaw-2016-Annual-Global-Investment-Conference.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - Sep 6, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today announced that the Company will present at the Rodman & Renshaw 18<sup>th</sup> Annual Global Investment conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY. </p>]]></content> <dc:identifier>1051557</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/08/09/1051554/0/en/Stellar-Biotechnologies-Reports-Third-Quarter-2016-Financial-Results-and-Operational-Highlights.html</id> <title type="text">Stellar Biotechnologies Reports Third Quarter 2016 Financial Results and Operational Highlights </title> <published>2016-08-09T12:00:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/08/09/1051554/0/en/Stellar-Biotechnologies-Reports-Third-Quarter-2016-Financial-Results-and-Operational-Highlights.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - Aug 9, 2016) - <strong>Stellar Biotechnologies, Inc. ("Stellar" or "the Company")</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announces its financial results for its third fiscal quarter and nine months ended June 30, 2016.</p>]]></content> <dc:identifier>1051554</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/08/04/1051552/0/en/Stellar-Biotechnologies-Announces-Third-Quarter-2016-Corporate-Update-Conference-Call.html</id> <title type="text">Stellar Biotechnologies Announces Third Quarter 2016 Corporate Update Conference Call </title> <published>2016-08-04T12:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/08/04/1051552/0/en/Stellar-Biotechnologies-Announces-Third-Quarter-2016-Corporate-Update-Conference-Call.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - Aug 4, 2016) - <strong>Stellar Biotechnologies, Inc. ("Stellar" or "the Company") </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), will host its third quarter 2016 corporate update conference call and live webcast on Wednesday, August 10, at 1:30pm ET / 10:30am PT.</p>]]></content> <dc:identifier>1051552</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/07/19/1051550/0/en/Stellar-Biotechnologies-and-Neovacs-Announce-Formation-of-New-Company-Neostell-S-A-S-in-France.html</id> <title type="text">Stellar Biotechnologies and Neovacs Announce Formation of New Company Neostell S.A.S. in France </title> <published>2016-07-19T12:00:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/07/19/1051550/0/en/Stellar-Biotechnologies-and-Neovacs-Announce-Formation-of-New-Company-Neostell-S-A-S-in-France.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA and PARIS, FRANCE and BOSTON, MA--(Marketwired - Jul 19, 2016) - <strong>Stellar Biotechnologies, Inc. ("Stellar") </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>) and <strong>Neovacs S.A. ("Neovacs")</strong> (Alternext Paris: ALNEV) today announced the formation of <strong>Neostell S.A.S. ("Neostell")</strong>, a simplified stock corporation headquartered in France, to carry out the business of the companies' joint venture, previously announced on May 11, 2016, to manufacture and sell conjugated therapeutic vaccines using Stellar's Keyhole Limpet Hemocyanin (KLH).</p>]]></content> <dc:identifier>1051550</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/07/06/1051548/0/en/Stellar-Biotechnologies-Announces-Closing-of-Registered-Direct-Offering.html</id> <title type="text">Stellar Biotechnologies Announces Closing of Registered Direct Offering </title> <published>2016-07-06T16:00:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/07/06/1051548/0/en/Stellar-Biotechnologies-Announces-Closing-of-Registered-Direct-Offering.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - Jul 6, 2016) - <em>Stellar Biotechnologies, Inc. ("Stellar" or "the Company")</em> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announced today that it has closed its previously announced $6.75 million sale of 1,687,500 common shares in a registered direct offering and unregistered warrants to purchase up to 1,265,626 unregistered common shares in a private placement. The combined purchase price for one registered common share and one unregistered warrant to purchase 0.75 of an unregistered common share was $4.00. The warrants have an exercise price of $4.50 per full share, are non-exercisable for 6 months and terminate 5 years from the time the warrants are first exercisable.</p>]]></content> <dc:identifier>1051548</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/06/30/1051547/0/en/Stellar-Biotechnologies-Announces-Pricing-of-6-75-Million-Registered-Direct-Offering.html</id> <title type="text">Stellar Biotechnologies Announces Pricing of $6.75 Million Registered Direct Offering </title> <published>2016-06-30T12:45:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/06/30/1051547/0/en/Stellar-Biotechnologies-Announces-Pricing-of-6-75-Million-Registered-Direct-Offering.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - Jun 30, 2016) - <em>Stellar Biotechnologies, Inc. ("Stellar" or "the Company") </em>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announced today that it has entered into definitive agreements to sell 1,687,500 common shares in a registered direct offering and unregistered warrants to purchase up to 1,265,625 unregistered common shares in a private placement. The combined purchase price for one registered common share and one unregistered warrant to purchase 0.75 of an unregistered common share will be $4.00. The warrants have an exercise price of $4.50 per full share, are non-exercisable for 6 months and will terminate 5 years from the time the warrants are first exercisable. The closing of the offering is expected to occur on or about July 6, 2016, subject to the satisfaction of customary closing conditions.</p>]]></content> <dc:identifier>1051547</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/06/02/1051543/0/en/Stellar-Biotechnologies-to-Present-at-LD-Micro-Invitational-Conference.html</id> <title type="text">Stellar Biotechnologies to Present at LD Micro Invitational Conference </title> <published>2016-06-02T12:00:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/06/02/1051543/0/en/Stellar-Biotechnologies-to-Present-at-LD-Micro-Invitational-Conference.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - Jun 2, 2016) - <strong>Stellar Biotechnologies, Inc. ("Stellar" or "the Company")</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today announced that the Company will present at the LD Micro Invitational Conference, to be held June 7-9, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.</p>]]></content> <dc:identifier>1051543</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/05/25/1051539/0/en/Stellar-Biotechnologies-Named-as-a-2016-California-Small-Business-of-the-Year.html</id> <title type="text">Stellar Biotechnologies Named as a 2016 California Small Business of the Year </title> <published>2016-05-25T13:00:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/05/25/1051539/0/en/Stellar-Biotechnologies-Named-as-a-2016-California-Small-Business-of-the-Year.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - May 25, 2016) - <strong>Stellar Biotechnologies, Inc. ("Stellar" or "Company") </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announced that the Company will be recognized as a 2016 California Small Business of the Year in ceremonies today at the state capitol in Sacramento, California. </p>]]></content> <dc:identifier>1051539</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/05/23/1051535/0/en/Stellar-Biotechnologies-Appoints-Michael-L-Klein-Ph-D-as-Vice-President-of-Chemistry-Manufacturing-and-Controls-CMC.html</id> <title type="text">Stellar Biotechnologies Appoints Michael L. Klein, Ph.D. as Vice President of Chemistry, Manufacturing and Controls (CMC) </title> <published>2016-05-23T12:30:00Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/05/23/1051535/0/en/Stellar-Biotechnologies-Appoints-Michael-L-Klein-Ph-D-as-Vice-President-of-Chemistry-Manufacturing-and-Controls-CMC.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - May 23, 2016) - <strong>Stellar Biotechnologies, Inc. ("Stellar" or "Company")</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today announced the appointment of Michael L. Klein, Ph.D. as Vice President of Chemistry, Manufacturing and Controls ("CMC"). Dr. Klein will assume management responsibility for the Company's pharmaceutical manufacturing and product development functions and serve as the Company's representative on all activities related to CMC.</p>]]></content> <dc:identifier>1051535</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/05/11/1051530/0/en/Stellar-Biotechnologies-and-Neovacs-Sign-Joint-Venture-Agreement-to-Manufacture-Conjugated-Therapeutic-Vaccines-With-Stellar-KLH-TM.html</id> <title type="text">Stellar Biotechnologies and Neovacs Sign Joint Venture Agreement to Manufacture Conjugated Therapeutic Vaccines With Stellar KLH(TM) </title> <published>2016-05-11T14:02:53Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/05/11/1051530/0/en/Stellar-Biotechnologies-and-Neovacs-Sign-Joint-Venture-Agreement-to-Manufacture-Conjugated-Therapeutic-Vaccines-With-Stellar-KLH-TM.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA and PARIS, FRANCE and BOSTON, MA--(Marketwired - May 11, 2016) - <strong> Stellar Biotechnologies, Inc. ("Stellar") </strong>(<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>) <strong>and Neovacs S.A. ("Neovacs") </strong>(Alternext Paris: ALNEV) today announced their entry into a joint venture agreement to manufacture and sell conjugated therapeutic vaccines (the "Joint Venture") using Stellar's proprietary Keyhole Limpet Hemocyanin (KLH). </p>]]></content> <dc:identifier>1051530</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/05/09/1051527/0/en/Stellar-Biotechnologies-Reports-Second-Quarter-2016-Financial-Results-and-Operational-Highlights.html</id> <title type="text">Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights </title> <published>2016-05-09T21:18:54Z</published> <updated>2024-11-25T23:00:43Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/05/09/1051527/0/en/Stellar-Biotechnologies-Reports-Second-Quarter-2016-Financial-Results-and-Operational-Highlights.html" /> <content type="html"><![CDATA[<p>PORT HUENEME, CA--(Marketwired - May 9, 2016) - <strong> Stellar Biotechnologies, Inc. ("Stellar" or "the Company")</strong> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="SBOT">SBOT</ticker>), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announces its financial results for its second fiscal quarter ended March 31, 2016.</p>]]></content> <dc:identifier>1051527</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Stellar Biotechnologies, Inc.</dc:contributor> <dc:modified>Fri, 15 Sep 2017 04:36 GMT</dc:modified> </entry> </feed>